Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARRY Array Technologies	$7.75 +11.4%	$6.82	$3.76 ▼ $12.06	$1.18B	1.74	6.37 million shs	6.67 million shs
BGNE BeiGene		$194.32	$142.00 ▼ $248.16	$18.03B	0.57	337,591 shs	331,608 shs
ELAN Elanco Animal Health	$14.64 -0.5%	$12.93	$8.02 ▼ $15.78	$7.27B	1.67	5.07 million shs	2.01 million shs
MYL Mylan	$15.86	$15.57	$12.75 ▼ $23.11	$8.59B	1.45	6.49 million shs	4,016 shs
OPHLF Ono Pharmaceutical	$9.33	$10.74	$9.20 ▼ $16.05	$4.38B	0.49	1,317 shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARRY Array Technologies	0.00%	+20.34%	+3.33%	+78.98%	-19.44%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+25.62%
ELAN Elanco Animal Health	0.00%	+2.27%	+4.98%	+63.67%	+2.95%
MYL Mylan	0.00%	0.00%	0.00%	0.00%	0.00%
OPHLF Ono Pharmaceutical	0.00%	0.00%	-10.80%	-0.74%	-32.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARRY Array Technologies	3.2946 of 5 stars	3.2	3.0	0.0	0.0	1.6	0.0	3.1
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	2.3907 of 5 stars	1.3	4.0	0.0	0.3	2.0	1.7	1.3
MYL Mylan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARRY Array Technologies	2.48	Hold	$9.13	17.74% Upside
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
ELAN Elanco Animal Health	2.50	Moderate Buy	$15.33	4.74% Upside
MYL Mylan	0.00	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARRY, MYL, BGNE, ELAN, and OPHLF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $17.00
6/27/2025	ARRY Array Technologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00
6/26/2025	ELAN Elanco Animal Health	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
6/20/2025	ARRY Array Technologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
6/20/2025	ARRY Array Technologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$12.00 ➝ $13.00
6/20/2025	ARRY Array Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $8.00
5/20/2025	ARRY Array Technologies	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
5/19/2025	ARRY Array Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
5/19/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00
5/16/2025	ARRY Array Technologies	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
5/8/2025	ARRY Array Technologies	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.50

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARRY Array Technologies	$915.81M	1.29	$2.83 per share	2.74	($0.78) per share	-9.94
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
ELAN Elanco Animal Health	$4.44B	1.64	$2.25 per share	6.50	$12.33 per share	1.19
MYL Mylan	$11.50B	0.75	$8.76 per share	1.81	$23.02 per share	0.69
OPHLF Ono Pharmaceutical	$3.20B	1.37	$1.08 per share	8.66	$11.07 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARRY Array Technologies	-$240.39M	-$1.85	N/A	11.07	0.60	-21.21%	1,227.67%	9.83%	8/6/2025 (Estimated)
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
ELAN Elanco Animal Health	$338M	$0.74	19.78	16.45	2.86	8.43%	7.54%	3.57%	8/6/2025 (Estimated)
MYL Mylan	$16.80M	$4.42	29.92	3.52	2.01	2.35%	20.43%	7.72%	N/A
OPHLF Ono Pharmaceutical	$330.31M	$0.70	13.33	∞	N/A	10.24%	6.20%	4.66%	7/28/2025 (Estimated)

Latest ARRY, MYL, BGNE, ELAN, and OPHLF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	ELAN Elanco Animal Health	$0.31	$0.37	+$0.06	$0.14	$1.17 billion	$1.19 billion
5/6/2025	Q1 2025	ARRY Array Technologies	$0.09	$0.13	+$0.04	$0.02	$264.14 million	$302.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARRY Array Technologies	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
MYL Mylan	N/A	N/A	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARRY Array Technologies	N/A	2.39	1.93
BGNE BeiGene	0.05	1.93	1.72
ELAN Elanco Animal Health	0.68	2.71	1.46
MYL Mylan	0.84	0.93	0.53
OPHLF Ono Pharmaceutical	0.13	3.07	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARRY Array Technologies	N/A
BGNE BeiGene	48.55%
ELAN Elanco Animal Health	97.48%
MYL Mylan	88.18%
OPHLF Ono Pharmaceutical	N/A

Insider Ownership

Company	Insider Ownership
ARRY Array Technologies	0.45%
BGNE BeiGene	7.43%
ELAN Elanco Animal Health	0.89%
MYL Mylan	0.59%
OPHLF Ono Pharmaceutical	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARRY Array Technologies	1,021	152.55 million	151.86 million	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
ELAN Elanco Animal Health	9,000	496.65 million	492.23 million	Optionable
MYL Mylan	35,000	541.55 million	N/A	Optionable
OPHLF Ono Pharmaceutical	3,853	469.71 million	N/A	Not Optionable

ARRY, MYL, BGNE, ELAN, and OPHLF Headlines

Recent News About These Companies

Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down - Here's Why

June 25, 2025 | marketbeat.com

Pharma company announces it will lay off 83 Boston-area employees

April 30, 2025 | msn.com

Pharmaceutical company to cut 83 Boston-area jobs in downsize

April 28, 2025 | masslive.comM

Ono Pharmaceutical Taps Jorna Therapeutics for RNA-Editing Drug Discovery Partnership

April 21, 2025 | precisionmedicineonline.comP

Ono Pharmaceutical Enhances Governance and Diversity Initiatives

March 24, 2025 | tipranks.com

Ono scoops Ionis' hematology candidate sapablursen for up to $940M

March 13, 2025 | bioworld.comB

Ono earmarks $940m to gain rare blood cancer therapy from Ionis

March 12, 2025 | msn.com

ONO-4915 by Ono Pharmaceutical for Autoimmune Disorders: Likelihood of Approval

January 5, 2025 | pharmaceutical-technology.comP

ONO-4685 by Ono Pharmaceutical for T-Cell Lymphomas: Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Risk adjusted net present value: What is the current valuation of Ono Pharmaceutical’s Vimseltinib?

December 16, 2024 | pharmaceutical-technology.comP

Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area

December 5, 2024 | tmcnet.com

Equillium keeps equilibrium in GVHD after Ono no-go

November 1, 2024 | bioworld.comB

Sanofi enters talks with private equity firm to sell controlling stake in consumer health unit Opella

October 11, 2024 | fiercepharma.comF

Ono, Boehringer add to cancer pipelines with licensing deals

October 10, 2024 | pharmaphorum.comP

Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical

October 7, 2024 | standard-journal.comS

Life-saving cancer drug a boon to patients in Japan, but price prompts debate

October 4, 2024 | mainichi.jpM

Nectar Classic Hybrid Mattress review 2024

September 24, 2024 | fortune.com

The best Plank mattresses of 2024, tested and reviewed

September 24, 2024 | fortune.com

Turbine Achieves Key Milestone in Collaboration with Ono Pharmaceutical

September 12, 2024 | tmcnet.com

DelveInsight Business Research, LLP: BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight

September 11, 2024 | finanznachrichten.de

MCLA-145 by Merus for Merkel Cell Carcinoma: Likelihood of Approval

September 9, 2024 | pharmaceutical-technology.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
3 Top Stocks Under $20 Riding the “Made in America” Wave
By Chris Markoch | July 3, 2025
View 3 Top Stocks Under $20 Riding the “Made in America” Wave

ARRY, MYL, BGNE, ELAN, and OPHLF Company Descriptions

Array Technologies NASDAQ:ARRY

$7.75 +0.79 (+11.35%)

Closing price 07/3/2025 03:36 PM Eastern

Extended Trading

$7.68 -0.08 (-0.97%)

As of 06:47 AM Eastern

Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products portfolio includes DuraTrack HZ v3, a single axis tracker; Array STI H250 that delivers a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance energy production. Array Technologies, Inc. was incorporated in 1987 and is headquartered in Albuquerque, New Mexico.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Elanco Animal Health NYSE:ELAN

$14.64 -0.08 (-0.54%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$14.65 +0.01 (+0.07%)

As of 06:12 AM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Mylan NASDAQ:MYL

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Ono Pharmaceutical OTCMKTS:OPHLF

$9.33 0.00 (0.00%)

As of 07/3/2025

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time